Claims for Patent: 10,603,314

Summary for Patent: 10,603,314

Title:	Method for treating gefitinib resistant cancer
Abstract:	The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
Inventor(s):	Haber; Daniel A. (Chestnut Hill, MA), Bell; Daphne Winifred (Chevy Chase, MD), Settleman; Jeffrey E. (Newton, MA), Sordella; Raffaella (Cold Spring Harbor, NY), Godin-Heymann; Nadia G. (Stanmore, GB), Kwak; Eunice L. (Marlborough, MA), Rabindran; Sridhar Krishna (Eagleville, PA)
Assignee:	The General Hospital Corporation (Boston, MA) Wyeth LLC (New York, NY)
Application Number:	11/883,474
Patent Claims:	1. A method for treating gefitinib and/or erlotinib resistant non-small cell lung cancer in a patient in need thereof, comprising administering daily to the patient having gefitinib and/or erlotinib resistant non-small cell lung cancer a pharmaceutical composition comprising a unit dosage of an irreversible epidermal growth factor receptor (EGFR) inhibitor that covalently binds to cysteine 773 residue in the ligand-binding pocket of EGFR or cysteine 805 residue in the ligand-binding pocket of erb-B2. 2. The method of claim 1, wherein the irreversible EGFR inhibitor is EKB-569 or HKI-357. 3. The method of claim 1, wherein the irreversible EGFR inhibitor covalently binds to cysteine 773 residue of EGFR. 4. The method of claim 1, wherein the irreversible EGFR inhibitor covalently binds to cysteine 805 residue of erb-B2. 5. The method of claim 1, wherein the method further comprises administering at least one other tyrosine kinase inhibitor. 6. The method of claim 1, wherein the method further comprises administering radiation. 7. The method of claim 1, wherein the route of administering is intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathecal, intrapleural, intrauterine, rectal, vaginal, topical, or intratumor. 8. The method of claim 1, wherein the route of administering is transmucosal or transdermal. 9. The method of claim 1, wherein the route of administering is oral.